<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Fluorouracil (5-FU) plus irinotecan combined with bevacizumab has significant activity in <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (mCRC), but S-1 has become a substitute for continuous infusion of 5-FU and has a very low incidence of <z:e sem="disease" ids="C0549410" disease_type="Disease or Syndrome" abbrv="">hand-foot syndrome</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>With the S-1 plus irinotecan regimen (SIR), the response rate was 62.5%, and the progression-free survival was 8.0 months </plain></SENT>
<SENT sid="2" pm="."><plain>We report here on an update of efficacy and safety of the SIR plus bevacizumab (SIRB) regimen as first line treatment for mCRC patients </plain></SENT>
<SENT sid="3" pm="."><plain>Fifty-one eligible patients with histologically confirmed advanced or <z:e sem="disease" ids="C0854750" disease_type="Neoplastic Process" abbrv="">recurrent colorectal cancer</z:e> received this treatment </plain></SENT>
<SENT sid="4" pm="."><plain>S-1 was administered orally on days 1-14 of a 21-day cycle </plain></SENT>
<SENT sid="5" pm="."><plain>Patients were assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg, 50 mg, or 60 mg </plain></SENT>
<SENT sid="6" pm="."><plain>Irinotecan (150 mg/m(2)) plus bevacizumab (7.5 mg/kg) were administered by intravenous infusion on day 1 </plain></SENT>
<SENT sid="7" pm="."><plain>Safety analysis identified a grade 3/4 <z:hpo ids='HP_0001875'>neutropenia</z:hpo> rate of 26% </plain></SENT>
<SENT sid="8" pm="."><plain>Other grade 3/4 toxicities were <z:hpo ids='HP_0002014'>diarrhea</z:hpo> (8%), <z:hpo ids='HP_0002018'>nausea</z:hpo> (6%), <z:hpo ids='HP_0002013'>vomiting</z:hpo> (2%), and <z:hpo ids='HP_0000822'>hypertension</z:hpo> (8%) </plain></SENT>
<SENT sid="9" pm="."><plain>The response rate was 67% and the median progression-free survival time was 373 days </plain></SENT>
<SENT sid="10" pm="."><plain>The SIRB regimen appears to be highly active and well tolerated as first-line treatment for mCRC </plain></SENT>
</text></document>